MedDataX Logo

The Effect of Skin Cleansers on the Skin Surface Microbiome

NCT ID: NCT03348917

Last Updated: 2018-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-28

Study Completion Date

2018-01-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study determines the effects of a single application of different antiseptic skin cleansers on the composition of the skin surface microbiome using next-generation sequencing (NGS) techniques. Twelve healthy volunteers will receive all three test products in a randomized order to compare the effects of each skin cleanser.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disinfectants and oral antiseptics including PVP-I are known to kill microorganisms to a variable extent, at a variable range of time points. Microorganisms may be protected from disinfectants by production of thick masses of cells and extracellular materials, or biofilms. Moreover, antiseptics should not lead to dysbiosis after use. Dysbiosis is a negative change in the microbiome of a particular skin or mucosal region. The Human Microbiome project showed, that every area has a specific microbiota in which the human host lives with an abundance of commensal, synergistic, and potentially pathogenic microorganisms. Antiseptics with efficacy gaps and resistance may induce such dysbiosis, especially after prolonged use. It is envisaged that twelve healthy volunteers will complete the study. Each healthy volunteer will apply the test product according to a developed protocol, between established wash out periods.

The ability of the test product (Commercially available - Betadine® 7.5% skin cleanser (PVP-I 7.5%)) compared to the reference products (commercially available 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol) and Plain non antibacterial soap - Guardian gel hand wash (not medicated)) to reduce resident and transient microflora will be assessed. The hand wash products will also be assessed for their ability to maintain and/or restore balanced microflora.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Twelve healthy volunteers will be randomized into three arms with three different treatment sequences with four healthy volunteers in each arm. Up to fifteen healthy volunteers may be recruited with the consideration that up to three subjects may drop out.
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors
Single

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment sequence Group 1

Treatment Sequence Group 1 = A -\> B -\> C

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Group Type ACTIVE_COMPARATOR

7.5% Povidone-Iodine [PVP-I]

Intervention Type DRUG

Betadine® 7.5% skin cleanser (PVP-I 7.5%)

4% chlorhexidine skin cleanser

Intervention Type DRUG

Unity antiseptic hand wash (no alcohol)

Plain non antibacterial soap

Intervention Type DRUG

Guardian gel hand wash (not medicated),

Treatment sequence Group 2

Treatment Sequence Group 2 = B -\> C -\> A

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Group Type ACTIVE_COMPARATOR

7.5% Povidone-Iodine [PVP-I]

Intervention Type DRUG

Betadine® 7.5% skin cleanser (PVP-I 7.5%)

4% chlorhexidine skin cleanser

Intervention Type DRUG

Unity antiseptic hand wash (no alcohol)

Plain non antibacterial soap

Intervention Type DRUG

Guardian gel hand wash (not medicated),

Treatment sequence Group 3

Treatment Sequence Group 3 = C -\> A -\>B

Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)

Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)

Group Type ACTIVE_COMPARATOR

7.5% Povidone-Iodine [PVP-I]

Intervention Type DRUG

Betadine® 7.5% skin cleanser (PVP-I 7.5%)

4% chlorhexidine skin cleanser

Intervention Type DRUG

Unity antiseptic hand wash (no alcohol)

Plain non antibacterial soap

Intervention Type DRUG

Guardian gel hand wash (not medicated),

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

7.5% Povidone-Iodine [PVP-I]

Betadine® 7.5% skin cleanser (PVP-I 7.5%)

Intervention Type DRUG

4% chlorhexidine skin cleanser

Unity antiseptic hand wash (no alcohol)

Intervention Type DRUG

Plain non antibacterial soap

Guardian gel hand wash (not medicated),

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects between age 21 to 65 years
* Must wear short sleeved shirts/blouses during each visit
* Non-smoker
* Good general and mental health with, in the opinion of investigator or the qualified medical designee:

1. No clinically significant and relevant abnormalities of medical history or physical examination;
2. Absence of any condition that would impact the subject's safety or health or affect the subject's ability to understand and comply with the study procedures.
* Prepared to use the provided wash products that do not contain any antimicrobials (non antibacterial shampoo \[Pantene® Pro-V\], non antibacterial body wash \[Dove®body wash\] and non antibacterial hand wash \[Guardian gel hand wash\]) after providing consent and during the whole study
* Healthy and intact skin in the test area (e.g., no skin allergy, visible bleeding, skin inflammation, skin ulcer or skin lesion, no need for cutaneous treatment)
* Must have given written informed consent
* Women of child-bearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.

Exclusion Criteria

* Women who are pregnant or have a positive urine pregnancy test or intending to become pregnant during the overall study period
* Women who are breast-feeding
* Allergy or contraindication to any test product substance (active or excipients)
* Any visible signs of skin dermatitis on the hands, e.g., eczema
* Use of anti-dandruff shampoo or any other shampoo/hand/body wash products apart from those provided, within 2 days prior to Visit 2 (Day 0) and also during the whole study
* Systemic or topical or oral antibiotic or antifungal in the past 2 months before Screening and during the study
* Medication use (e.g., lithium therapy, immunosuppressive medication, systemic or inhaled glucocorticoids) in the past 2 months before Screening and during the study
* Recent history (within the last 1 year) of alcohol or other substance abuse
* Known hyperthyroidism or other ongoing thyroid diseases
* Minor ailments such as like cough, cold, upper respiratory tract infection(s) within 2 weeks and during the study
* Any known serious ongoing disease
* Unwillingness or inability to comply with the requirements of the protocol
* Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) before Screening
* An employee of the sponsor or study site or their immediate family member
* Subject who has been treated with cancer within the last 1 year.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genome Institute of Singapore

OTHER

Sponsor Role collaborator

Mundipharma Manufacturing Pte Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nisha Su Yien Subash Chandran

Role: PRINCIPAL_INVESTIGATOR

National University Hospital, Singapore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National University Hospital Singapore

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BTD16-SG-402

Identifier Type: -

Identifier Source: org_study_id